Our Research Summary

Tikun Olam is on the cutting edge of medical cannabis research, using its proprietary strains and products in ongoing clinical trials in Israel's regulated market, with exceptional results and treatment success.

Operating for over a decade, Tikun Olam continues to develop and initiate partnerships and collaborations with physicians and scientists, led by Lihi Bar-Lev Schleider, a PhD student at the Ben-Gurion University of the Negev. 

Tikun Olam's patients data analysis overseen by Professor Victor Novack, Head of Soroka Clinical Research Center. Professor Raphael Mechoulam from the Hebrew university, has been involved in many of the published studies, along with many other pioneering researchers. 

Below the status of the studies:

Cannabis in ASD patients

Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy

80.1% of children showed Improvement after Treatment with Avidekel and Erez strains extracts.

Chief Researcher: Lihi Bar-Lev Schleider, Soroka University Medical Center Full article

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities

75% Improvement in ASD Comorbidities Symptoms, 43.1% Stated a Significant Improvement

Avidekel and Erez strains extracts used in retrospective cohort study examined the effects on 53 children and adolescents diagnosed with ASD.

Dr. Orit Stoler, Assaf Harofeh Medical Center, Israel Full article


Treatment of Crohn’s Disease with Cannabis- An Observational Study:

All Patients Stated a Positive Effect on their Crohn's Disease Activity

The retrospective research study was conducted by interviewing patients suffering from  Crohn’s disease.The study has found very positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, blood in stool samples, pain, etc.).

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

Published in: IMAJ - The Israel Medical Association Journal, 2011

To download the full study click here

Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Randomized Placebo-Controlled, Double-Blind Study:

90% Significant Reduction of Crohn's Disease Symptoms with No Side Effects;

Verification of full Remission in 50%

In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam's Erez strain to produce dramatic results with 50% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed. 

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

Published in: Clinica Gastroenterology& Hepatology 2013

To download the full study click here

The Anti-Inflammation and Anti-Pain Properties of Cannabis Extracts:

Strong Effectiveness of Avidekel on Inflammatory Symptoms in Comparison to Tramadol and Aspirin and Pure CBD

Laboratory research study that was conducted on rodents which examines the effect of extractions of the main strains developed by Tikun Olam on inflammation and pain, in comparison with placebo and isolated CBD.

Verification of strong effectiveness of Avidekel (in comparison to infection counteracting medicines Tramadol and Asperin) as well as a strong reactive strength in comparison to the administration of pure CBD.

Head Researcher: Prof. Ruth Gallily

Hospital: Hadassah University Hospital-Ein Kerem, Jerusalem, Israel

Published in: Pharmacology & Pharmacy, 2015, 6, 75‐85 

Full article 

The Effects of Cannabis on Appetite and Blood Indices of Geriatric Patients:

72.2% reduced medications, 50% improvement in spasticity

A long-term observational follow-up conducted to collect data from elderly nursing home patients that regularly use medical cannabis. The study measures parameters such as: nutritional blood work, caloric intake, weight, prescription drug usage, sepsis, trembling, spasticity, and quality of life measurements (mood, sleeping habits, etc.)

Head Researcher: Dr. Moshe Geitzen, Geriatrics

Location: Hadarim Nursing Home, Kibbutz Naan

Treating elderly with medical cannbais- special project, Tikun olam has accumulated data on a unique three year (2009-2013) research of treating old age with Tikun Olam Medical Cannabis strains and products in "Hadarim" Nursing Home. The project in "Hadarim" nursing home in kibbutz Na'an has finished and the results and data are helping treat the elderly in Israel, Canada and hopefully in the future the rest of the world. 

The Effects of Cannabis on Parkinson's Disorders:

76.9% reported positive effect on their general condition and mood, 64% reported improvement in pain and spasticity, 59% reported decreased tremors and improved quality of sleep.

The study is a research survey through questionnaires that examines the effects of cannabis on the motor and  non- motor symptoms, of patients with different movement disorders (Parkinson’s disease, Parkinson plus syndromes, dystonia, tics and Tourette syndrome and others) , including quality of life and activity of daily living as well as  the side effects resulting from the cannabis consumption. 

Head Researcher: Dr. Tanya Gurevich, Movement Disorders Unit

Hospital: Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Published in Clinical Neuropharmacology: November/December 2017 - Volume 40 - Issue 6 - p 268–272



1. Effects of Avidekel on Dystonia and Spasticity of Cerebral Palsy Paediatric Patients

Significant Improvement in Spasticity and Dystonia, Sleep Difficulties, Pain Severity and Quality of Life

Clinical random trial examined the effects of Avidekel oil on dystonia and spasticity in children who suffer from CP or genetic impairment.

Results have shown significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and quality of life was observed.  Adverse effect included worsening of seizures in two patients; behavioral changes in two patients; somnolence in one patient.

Head ResearcherDr. Luba Blumkin, Wolfson Hospital

The Journal of Child Neurology (JCN)  

2. Effects of Cannabis on children diagnosed with ASD (Autistic spectrum disorder)

The patients showed 75% improvement in ASD comorbidities symptoms

Retrospective cohort study of 53 patients. study product: Avidekel oil 1:20 and Erez oil 3%

Dr. Orit Stoler, Assaf Harofeh Medical Center

3. Effects of Medical Cannabis on Children and Adolescents with Epilepsy:

Most of the patients (89%) reported some reduction in seizure frequency

Retrospective cohort study of 74 patients.The purpose of the study to describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil including Abidkl  oil 1:20.

Chief Researcher: Dr. Michal Zadok

Medical centers: Sheba, Sourasky, Wolfson, Assaf Harofeh, MCU MOH

To download the full study click here



1.The Effects of Cannabis on Colitis:

Improvement of Ulcerative Colitis in Endoscopy and DAI index Reduction of Drug Consumption

Clinical research comparing a group of patients who will be given “Erez” strain cannabis cigarettes (0.5 grams per cigarette) and a group of patients who will be given placebo cigarettes (a total of two cigarettes per day) for a period of eight weeks, during which the effect of the substance on blood inflammation indices, life quality, medicine consumption, and adverse side effects etc., will be monitored.

Head Researcher:  Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

2. The Effects of Cannabis on Crohn's Disease:

Decrease in DAI index of Crohn's Disease patients and Reduced Drug Consumption

Clinical research comparing a test group, receiving the Avidekel strain, and a control group (placebo), in order to examine the effect of cannabis administered with oil on the inflammatory intestinal disease. The oil contains a high concentration of CBD (200 mg) and a low concentration of THC (59 mg) and is administered twice a day.

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel

4. Cannabis and IBD Data Collection:

92.5% Satisfaction in IBD Patients

50% Reduction in HBI index

Significant Decrease in Consumption of all Medications

Positive Gain of Weight and Improved Quality of Life

Large-scale long-term data collection study on patients with a permit for medical cannabis that suffer from inflammatory bowel disease (IBD) to determine the effect of cannabis use on the symptoms and adverse side effects of the disease over a long time period. The study will look at different ingestion methods and various cannabis strains to determine their impact.

Head Researcher: Dr. Timna Naftali, Gastroenterology

Hospital: Meir Medical Center, Kfar Saba, Israel



Patient Tracking:

92.1% of patients reported improvement with mild side effects.
Data analysis in order to examine the beneficial effects and side effects of Tikkun Olam products and varieties in various consumption methods, including indications.
Chief Researcher: Lihi Bar-Lev Schleider, Prof. Raphael Meshulam and Prof. Victor Novak
Hospital: Soroka University Medical Center

Cancer patients follow-up:

95.9% of CANCER patients reported an improvement in their condition.

Analysis of the data collection of patients licensed for cancer, in order to examine the effect of therapeutic medical cannabis of Tikun Olam.
Chief Researcher: Lihi Bar-Lev Schleider, Prof. Raphael Meshulam and Prof. Victor Novak
Hospital: Soroka University Medical Center

Monitoring of Geriatric patients:

93.7% of the patients reported an improvement in their general condition and a decrease in pain intensity from a median score of 8 (on a scale of 1-10) to a median score of 4. After half a year of treatment, 18.1% of patients completely discontinued or reduced the use of opioid analgesics.

The most common adverse events reported by patients were dizziness (9.7%) and dry mouth (7.1%).
Analysis of data collection of 2,736 licensed medical cannabis aged 65 and over in all indications.
Chief Researcher: Lihi Bar-Lev Schleider
Hospital: Soroka University Medical Center

Follow-up of Fibromyalgia patients:

Cannabis Effectively Treats Fibromyalgia, Decrease Pharmaceutical & Opioid Use 

A significant improvement in pain intensity and patients′ overall quality of life and fibromyalgia‐related symptoms after six months of Tikun Olam's medical cannabis therapy.
Journal of Clinical Medicine confirms, 2019 
Dr. Iftach Sagy, Soroka Medical Center, Israel


The Effects of Cannabis on Immune Response:

The effect of Extracts of Avidekel, Erez and Midnight on immune response in blood samples in which infection was induced.

Verification of a suppressing effect of natural cannabinoids on the release of inflammation triggering cytokines; indication of a possible inflammation preventing effect of CBD on the immune system.

Head ResearcherDr. Yishay Szekely

HospitalTel Aviv Sourasky